Navigation Links
Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting

IRVINE, Calif. and LONDON--(BUSINESS WIRE)--Apr 16, 2007 - Somanta Pharmaceuticals (OTCBB:SMPM) today announced that data from its Alchemix program will be presented later today at the American Association for Cancer Research Annual Meeting in Los Angeles.

The poster presentation is entitled "Cytotoxicity of novel alkylating anthraquinones in cells with DNA Nucleotide Excision Repair and DNA Mismatch Repair defects," and focuses on structure-activity studies on the company's novel technology for targeting and irreversibly binding to DNA / DNA processing enzymes. The studies reported in the poster were conducted at the Institute for Cancer Therapeutics at the University of Bradford, Bradford, United Kingdom (www.cancer.Brad.ac.uk) under the collaborative research agreement announced previously.

Somanata recently announced the company had signed a letter of intent to be acquired by Access Pharmaceuticals, Inc, (OTCBB:ACCP) an emerging oncology-focused biopharmaceutical company based in Dallas, Texas.

About Somanta Pharmaceuticals

Somanta Pharmaceuticals, Inc. ("Somanta") is a specialty oncology company with particular focus on in-licensing anti-cancer agents with substantial clinical data supporting safety and efficacy. To date, the Company has successfully in-licensed the rights to four products, each with a different mode of action and targeting eleven different cancer types.

Certain statements contained herein are "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Because these statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Specifically, factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statem ents include, but are not limited to: risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and in Somanta's compounds under development in particular; the potential failure of Somanta's compounds under development to prove safe and effective for treatment of disease; uncertainties inherent in the early stage of Somanta's compounds under development; failure to successfully implement or complete clinical trials; failure to receive marketing clearance from regulatory agencies for our compounds under development; acquisitions, divestitures, mergers, licenses or strategic initiatives that change Somanta's business, structure or projections; the development of competing products; uncertainties related to Somanta's dependence on third parties and partners; and those risks described in Somanta's filings with the SEC. Somanta disclaims any obligation to update these forward-looking statements.

Contact

Somanta Pharmaceuticals, Inc.
Terrance J. Bruggeman
Executive Chairman
949-706-3697
or
Agamemnon A. Epenetos
President and Chief Executive Officer
011-44 207 631 4868


'"/>




Related medicine technology :

1. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Research and Markets has announced the addition of the "Contraceptives - ... ... the US, Canada , Japan , ... Latin America , and Rest of World. Annual estimates and forecasts ... analysis is provided for these markets. Market data and analytics are derived ...
(Date:2/17/2017)...  Ethicon, Inc. today announced a definitive agreement ... medical device company that manufactures and markets the ... minimally invasive device for the surgical treatment of ... Ethicon to offer patients a safe and effective ... procedure. 1 This LINX ® ...
(Date:2/17/2017)... 2017 Theravance Biopharma, Inc. (NASDAQ: ... today announced the presentation of positive clinical data ... pan-Janus kinase (JAK) inhibitor designed to be intestinally ... the European Crohn,s and Colitis Organization (ECCO). In ... from its completed Phase 1 study of single-ascending ...
Breaking Medicine Technology:
(Date:2/18/2017)... , ... February 17, 2017 , ... Butler Mobility invited ... Stannah Stairlift and other Butler products. Ken was impressed with the safety and ... to endorse the product on his show. This endorsement by Ken Matthews can ...
(Date:2/17/2017)... ... 2017 , ... Smiles by Seese is a comprehensive family dental practice ... leads the practice as a skilled and highly credentialed dentist who is qualified to ... patients of all ages with excellence in general, restorative, and cosmetic dentistry . ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Webinar**, Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, ... be asking before selecting an FDA approval pathway? , How should they ...
(Date:2/17/2017)... ... 2017 , ... Program will serve more than 5,000 kids ... Soccer Foundation announced today that they have awarded nine grants to expand the ... soccer mentoring program, teaches kids the fundamentals of soccer while striving to help ...
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across the nation, Onslow Memorial ... by the Hospital Readmission Reduction Program (HRRP), the return of a patient to the ... across the nation. While many providers are struggling to leverage limited resources and technology, ...
Breaking Medicine News(10 mins):